15 minutes to Delve

From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.

Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.

Contributor
Brendan Duck, Ryan Paul
25 August 2021
15 minutes to Delve

When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk. 

Contributor
Brendan Duck, Ryan Paul
24 August 2021
1 minute to Read

Pharmac has identified five key drivers of medicine access equity in New Zealand. Read on to learn about the drivers and how you can implement them in your place of work. 

13 July 2021
2 minutes to Read + 43 minutes to Explore

Focusing on the experiences of older Māori in primary care, this course comprises four short videos, an independent reflection, downloadable posters and additional resources.

The course is endorsed by RNZCGP and CNA(NZ) and meets PCNZ recertification requirements. Reflection templates are included for you to complete.

Contributor
Jo Hikaka
18 May 2021

This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.

Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.

This is a Measuring and Improving Outcomes (MIO) activity that meets RNZCGP CPD requirements.

Contributor
He Ako Hiringa
3 May 2021
20 minutes to Read

Māori attitudes to healthcare today are deeply rooted in New Zealand history. In this article, Deborah Bassett-Clarke discusses some reasons why the current model of pharmacy practice does not always meet the needs of Māori and may actually cause health inequities. Understanding these factors is an important first step to improving outcomes for Māori.

Contributor
Deborah Bassett-Clarke
30 April 2021
2 minutes to Delve

Medicine affordability is one of the five drivers of medicine access equity.

Up to 40 per cent of people continue to pay prescription copayments even though they are entitled to an exemption.No person or family should pay more than $100 per annum for subsidised medicines.

Read the HAH bulletin to find out more. 

Contributor
He Ako Hiringa
30 April 2021